Home Dental Radiology Radiographic evidence of treatment with bisphosphonates

Radiographic evidence of treatment with bisphosphonates

by adminjay

  • 1

    Ruggiero S L, Dodson T B, Fantasia J et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg 2015; 72: 1938 956.

  • 2

    Health and Social Care Information Centre. Prescriptions Dispensed in the Community: England 2002–12. 30 July 2013. Available at: https://catalogue.ic.nhs.uk/publications/prescribing/primary/pres-disp-com-eng-2002-12/pres-disp-com-eng-2002-12-rep.pdf (accessed March 2016).

  • 3

    British Orthopaedic Association. The care of patients with fragility fracture. London: British Orthopaedic Association, 2007.

  • 4

    Osteoporosis: assessing the risk of fragility fracture. NICE guidelines [CG146]. August 2012. Available at: https://www.nice.org.uk/guidance/cg146/chapter/1-Guidance#ftn.footnote_8 (accessed 3 September 2015).

  • 5

    FRAX –The WHO Fracture risk assessment tool. Available at: http://www.shef.ac.uk/FRAX/ (accessed 3 September 2015).

  • 6

    Devlin H, Karayianni K, Mitsea A et al. Diagnosing osteoporosis by using dental panoramic radiographs: The OSTEODENT project. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: 821–828.

  • 7

    Karayianni K, Horner K, Mitsea A et al. Accuracy in osteoporosis diagnosis of a combination of mandibular cortical width measurement on dental panoramic radiographs and a clinical risk index (OSIRIS): the OSTEODENT project. Bone 2007; 40: 223–229.

  • 8

    Calciolari E, Donos N, Park J C, Petrie A, Mardas N . Panoramic measures for oral bone mass in detecting osteoporosis: a systematic review and meta-analysis. J Dent Res 2015; 94 (3 Suppl): 17S–27S.

  • 9

    Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended). NICE, October 2008. Available at: https://www.nice.org.uk/guidance/ta161/chapter/1-guidance (accessed 27 July 2015).

  • 10

    Zaman M U, Nakamoto T, Tanimoto K . A retrospective study of digital subtraction technique to detect sclerotic changes in alveolar bone on intraoral radiographs of bisphosphonate-treated patients. Dentomaxillofac Radiol 2013; 42: 20130242. 10.1259/dmfr.20130242. Epub 2013 Oct 29.

  • 11

    Liew S, Steines S, Jeffcoat M et al. Dental X-rays Identify women with low hip and spine BMD. Imaging Therapeutics Inc., 2005.

  • 12

    Horner K, Karayianni K, Mitsea A et al. The mandibular cortex on radiographs as a tool for osteoporosis risk assessment: the OSTEODENT project. J Clin Densitom 2007; 10: 138–146.

  • 13

    Phal P, Myall R W T, Assael L A, Weissman J L . Imaging findings of bisphosphonate associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 2007; 28: 1139–1145.

  • 14

    Hutchinson M, O’Ryan F, Chavez V et al. Radiographic Findings in Bisphosphonate-Treated Patients With Stage 0 Disease in the Absence of Bone Exposure. J Oral Maxillofac Surg 2010; 68: 2232–2240.

  • 15

    Donetti E, Gualerzi A, Sardella A, Lodi G, Carrassi A, Sforza C . Alendronate impairs epithelial adhesion, differentiation and proliferation in human oral mucosa. Oral Dis 2014; 20: 466–472.

  • 16

    Ravosa M J, Ning J, Liu Y, Stack M S . Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts. Arch Oral Biol 2011; 56: 491–498.

  • 17

    Shiomi K, Nagata Y, Kiyono T, Harada A, Hashimoto N . Differential impact of the bisphosphonate alendronate on undifferentiated and terminally differentiated human myogenic cells. J Pharm Pharmacol 2014; 66: 418–427.

  • 18

    Santini D, Virzi V, Fratto M E et al. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Curr Cancer Drug Targets 2010; 10: 46–54.

  • 19

    Polymeri A A, Kodovazenitis G J, Polymeris A D, Komboli M . Bisphosphonates: clinical applications and adverse events in dentistry. Oral Health Prev Dent 2015; 13: 289–299.

  • 20

    Torres S R, Chen C S K, Leroux B G et al. Mandibular inferior cortical bone thickness on panoramic radiographs in patients using bisphosphonates. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 119: 584–592.

  • 21

    Takaishi Y, Ikeo T, Nakajima M, Miki T, Fujita T . A pilot case-control study on the alveolar bone density measurement in risk assessment for bisphosphonate-related osteonecrosis of the jaw. Osteoporos Int 2010; 21: 815–825.

  • 22

    Marx R, Cillo J, Ulloa J . Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397–2410.

  • 23

    Fleisher K E, Welch G, Kottal S, Craig R G, Saxena D, Glickman R S . Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110: 509–516.

  • 24

    Kos M . Association of dental and periodontal status with bisphosphonate-related osteonecrosis of the jaws. A retrospective case controlled study. Arch Med Sci 2014; 10: 117–123.

  • Source link

    Related Articles